发明名称 |
Anti-cMET antibody |
摘要 |
Antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor, with an improved antagonistic activity, said antibody comprising a modified hinge region. A composition comprising such an antibody antagonist to c-Met and its use as a medicament for treating cancer. |
申请公布号 |
US9469691(B2) |
申请公布日期 |
2016.10.18 |
申请号 |
US201414248741 |
申请日期 |
2014.04.09 |
申请人 |
PIERRE FABRE MEDICAMENT |
发明人 |
Goetsch Liliane;Wurch Thierry;Bes Cédric |
分类号 |
A61K39/395;C07K16/28;A61K45/06;A61K31/337;A61K31/517;A61K31/5377;A61K31/555;A61K31/7068;A61K33/24;A61K39/00 |
主分类号 |
A61K39/395 |
代理机构 |
Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P. |
代理人 |
Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P. |
主权项 |
1. A monoclonal chimeric or humanized anti-cMet antibody comprising:
a heavy chain comprising complementarity determining regions (CDR) CDR-H1, CDR-H2, and CDR-H3 comprising amino acid sequences SEQ ID Nos. 1, 2, and 3, respectively; a light chain comprising CDR-L1, CDR-L2, and CDR-L3 comprising amino acid sequences SEQ ID Nos. 5, 6, and 7, respectively; and a modified hinge region comprising the amino acid sequence SEQ ID No. 26. |
地址 |
Boulogne-Billancourt FR |